Protein kinase Cb mediates downregulated expression of glucagon-like peptide-1receptor in hypertensive rat renal arteries

Journal of Hypertension

Volumn 33, Issue 4, 2015, Pages 784-790

  Liu, Limei ^a   Liu, Jian ^b   Gao, Yuansheng ^a   Ng, Chi Fai ^c   Yu, Xiaoxing ^a   Dou, Dou ^a   Huang, Yu ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glucagon like peptide 1 receptor; Hypertension; Protein kinase C; Renal artery

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HISPIDIN; N(G) NITROARGININE METHYL ESTER; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C DELTA; ROTTLERIN; UNCLASSIFIED DRUG; PEPTIDE; PHORBOL ESTER; PHORBOL-12-MYRISTATE; VENOM;

ANIMAL TISSUE; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EX VIVO STUDY; IMMUNOFLUORESCENCE; KIDNEY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; AGED; ANIMAL; DOWN REGULATION; ENZYMOLOGY; HUMAN; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION; WISTAR KYOTO RAT;

AGED; ANIMALS; BLOOD PRESSURE; DOWN-REGULATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PEPTIDES; PHORBOL ESTERS; PROTEIN KINASE C BETA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENAL ARTERY; SIGNAL TRANSDUCTION; VASODILATION; VENOMS;

EID: 84938934863     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000480     Document Type: Conference Paper

References (38)

1. Collett JA, Hart AK, Patterson E, Kretzer J, Osborn JL. Renal angiotensin II type 1 receptor expression and associated hypertension in rats with minimal SHR nuclear genome. Physiol Rep 2013; 1:e00104.
2. Hassan N, El-Bassossy HM, Zakaria MN. Heme oxygenase-1 induction protects against hypertension associated with diabetes: effect on exaggerated vascular contractility. Naunyn Schmiedebergs Arch Pharmacol 2013; 386:217-226.
3. Da Costa CA, de Oliveira PR, de Bem GF, de Cavalho LC, Ognibene DT, da Silva AF, et al. Euterpe oleracea Mart.-derived polyphenols prevent endothelial dysfunction and vascular structural changes in renovascular hypertensive rats: role of oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 2012; 385:1199-1209.
4. Hropot M, Langer KH, Wiemer G, Grotsch H, Linz W. Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. Naunyn Schmiedebergs Arch Pharmacol 2003; 367:312-317.
5. Kes P, Basic-Jukic N, Ljutic D, Brunetta-Gavranic B. The role of arterial hypertension in developement of chronic renal failure. Acta Med Croatica 2011; 65 (Suppl. 3):78-84.
6. Sugama I, Kohagura K, Yamazato M, Nakamura T, Shinzato T, Ohya Y. Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats. J Hypertens 2014; 32:534-541.
7. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005; 1:22-31.
8. Kulasa KM, Henry RR. Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother 2009; 10:2415-2432.
9. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215.
10. Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011; 384:197-207.
11. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012; 60:833-841.
12. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21:1125-1135.
13. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48:736-743.
14. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54:965-978.
15. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61:2967-2979.
16. Von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens 2014; 23:54-60.
17. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation 2008; 117:2340-2350.
18. Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. Eur J Pharmacol 2013; 720:158-165.
19. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19:567-575.
20. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressurelowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15:737-749.
21. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56:1551-1558.
22. Liu L, Liu J, Tian XY, Wong WT, Lau CW, Xu A, et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal 2014; 21:1571-1581.
23. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013; 33:2252-2260.
24. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110:43-52.
25. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretinbased therapies. J Am Soc Hypertens 2009; 3:245-259.
26. Duca FA, Sakar Y, Covasa M. Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist exendin-4. Diabetes 2013; 62:2410-2415.
27. Barakat GM, Moustafa ME, Bikhazi AB. Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats. Biochem Genet 2012; 50:922-935.
28. Dempsey EC, Cool CD, Littler CM. Lung disease and PKCs. Pharmacol Res 2007; 55:545-559.
29. Choi YH, Jin GY, Li LC, Yan GH. Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/ Akt/mTOR/HIF-1 alpha/VEGF pathway. PLoS One 2013; 8:e81773.
30. Tabet F, Schiffrin EL, Touyz RM. Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. J Hypertens 2005; 23:2005-2012.
31. Mangoura D, Sun Y, Li C, Singh D, Gutmann DH, Flores A, et al. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene 2006; 25:735-745.
32. Dey D, Basu D, Roy SS, Bandyopadhyay A, Bhattacharya S. Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Mol Cell Endocrinol 2006; 246:60-64.
33. Sasajima H, Shima H, Toyoda Y, Kimura K, Yoshikawa A, Hano T, et al. Increased Ca2 sensitivity of contractile elements via protein kinase C in alpha-toxin permeabilized SMA from young spontaneously hypertensive rats. Cardiovasc Res 1997; 36:86-91.
34. Fareh J, Touyz RM, Schiffrin EL, Thibault G. Altered cardiac endothelin receptors and protein kinase C in deoxycorticosterone-salt hypertensive rats. J Mol Cell Cardiol 2000; 32:665-676.
35. Das M, Dempsey EC, Bouchey D, Reyland ME, Stenmark KR. Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase c isozymes. Am J Respir Cell Mol Biol 2000; 22:15-25.
36. Snow JB, Gonzalez Bosc LV, Kanagy NL, Walker BR, Resta TC. Role for PKCbeta in enhanced endothelin-1-induced pulmonary vasoconstrictor reactivity following intermittent hypoxia.AmJ Physiol Lung Cell Mol Physiol 2011; 301:L745-L754.
37. Morquecho-Leon MA, Bazua-Valenti S, Romero-Avila MT, Garcia-Sainz JA. Isoforms of protein kinase C involved in phorbol ester-induced sphingosine 1-phosphate receptor 1 phosphorylation and desensitization. Biochim Biophys Acta 2014; 1843:327-334.
38. Zhang XH, Zheng B, Gu C, Fu JR, Wen JK. TGF-beta1 downregulates AT1 receptor expression via PKC-delta-mediated Sp1 dissociation from KLF4 and Smad-mediated PPAR-gamma association with KLF4. Arterioscler Thromb Vasc Biol 2012; 32:1015-1023.